ProPhase Labs, Inc. Proceeds from Convertible Debt
ProPhase Labs, Inc. (PRPH) reported Proceeds from Convertible Debt of $392.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-19.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromConvertibleDebt · last filed 2026-08-19
- ProPhase Labs, Inc. proceeds from convertible debt for the quarter ending 2026-06-30 was $0.00.
- ProPhase Labs, Inc. proceeds from convertible debt for the quarter ending 2026-03-31 was $392.00K.
- ProPhase Labs, Inc. proceeds from convertible debt for the quarter ending 2025-12-31 was $0.00.
- ProPhase Labs, Inc. proceeds from convertible debt for the quarter ending 2024-12-31 was $0.00.
- ProPhase Labs, Inc. proceeds from convertible debt for fiscal 2025 was $3.00M.
- ProPhase Labs, Inc. proceeds from convertible debt for fiscal 2024 was $0.00.
| Period end | Proceeds from Convertible Debt 3 month | Proceeds from Convertible Debt 6 month | Proceeds from Convertible Debt 9 month | Proceeds from Convertible Debt 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q/A 3 month · filed 2026-08-19 | $392.00K 10-Q · filed 2026-08-19 | $392.00K derived: sum of 3 quarters · filed 2026-08-19 | |
| 2026-03-31 | $392.00K 10-Q/A · filed 2026-07-09 | $392.00K derived: sum of 2 quarters · filed 2026-07-09 | ||
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-01 | $3.00M 10-K · filed 2026-06-01 | ||
| 2025-09-30 | $3.00M 10-Q · filed 2025-11-19 | |||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-01 | $0.00 10-K · filed 2026-06-01 | ||
| 2024-09-30 | $0.00 10-Q · filed 2025-11-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |